

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/616,223 07/14/00 NADEL

J UCSF-085CIP

HM12/0828

PAULA A. BORDEN
BOZICEVIC, FIELD & FRANCIS LLP
SUITE 200
200 MIDDLEFIELD ROAD
MENLO PARK CA 94025

EXAMINER

ZARA, J

ART UNIT

PAPER NUMBER

1635

DATE MAILED:

08/28/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary	Application No.	Applicant(s)
	09/616,223	NADEL ET AL.
	Examiner	Art Unit
	Jane Zara	1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-26 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

KATRINA TURNER
PATENT ANALYST

Attachment(s)

- 15) Notice of References Cited (PTO-892)
- 16) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
- 18) Interview Summary (PTO-413) Paper No(s) _____.
- 19) Notice of Informal Patent Application (PTO-152)
- 20) Other: _____.

File

DETAILED ACTION

Claims 1-26 are pending in the instant application.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-3, 10, 12-20 and 26, drawn to compositions and methods for reducing goblet cell hyperplasia in an organism's airway comprising the administration of a kinase inhibitor, classified in class 514, subclass 1.
- II. Claims 1, 4-6, 12-17, 21-23 and 26, drawn to compositions and methods for reducing goblet cell hyperplasia in an organism's airway comprising the administration of antibodies, classified in class 424, subclasses 130.1, 141.1 and 143.1.
- III. Claims 1, 7-9, 11-17 and 24-26, drawn to compositions and methods for reducing goblet cell hyperplasia in an organism's airway comprising the administration of an antagonist which inhibits release of a transmembrane EGF-R ligand, classified in class 424, subclass 9.2.

Applicants should note that several claims which appear in multiple groups, particularly claims 1, 12-17 and 26, will be examined according to the limitations of the elected group since said claims were found to be generic to patentably distinct groups.

Art Unit: 1635

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions I and II and III are unrelated because they comprise compositions which are chemically, biologically, structurally and functionally distinct from each other and thus one does not render the other obvious. The kinase inhibitors of Group I are not required to make the antibodies or Group II or the antagonists of Group III, the antibodies of Group II are not required to make the kinase inhibitors of Group I or the antagonists of Group III, and the antagonists of Group III are not required to make the kinase inhibitors of Group I or the antibodies of Group II. The modes of action and functions of each Group are different and distinct: Group I comprises kinase inhibitors, Group II comprises antibodies which bind to either EGF or EGF-R, and Group III comprises antagonists which inhibit release of a transmembrane EGF-R ligand. In addition, the methods of Groups I and II and III comprise steps which are not required for or present in the methods of the other groups: administration of a kinase inhibitor (Group I); administration of an antibody (Group II); and administration of an inhibitor of release of a transmembrane EGF-R ligand (Group III). Therefore, the inventions of these three groups are capable of supporting separate patents.

Art Unit: 1635

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Conclusion

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone numbers for the Group are (703) 308-4242 and (703) 305-3014. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Art Unit: 1635

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(703) 306-5820**. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on **(703) 308-0447**. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is **(703) 305-3413**. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is **(703) 308-0196**.



ANDREW WANG
PRIMARY EXAMINER

JZ

August 24, 2001